Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | HPGD | P15428 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.46 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL977997 | 0.87 | HSP90AA1 (0.63) | HSP90AA1KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL19033787 | 0.87 | HSP90AA1 (0.63) | HSP90AA1KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL20677772 | 0.81 | HSP90AA1 (0.58) | HSP90AA1ALDH1A1NAPRTMAPK1TSHR | |
| SCHEMBL20570242 | 0.81 | CYP1A1 (0.56) | HSP90AA1KMT2AGPR52ALDH1A1HPGD | |
| SCHEMBL20677796 | 0.80 | HSP90AA1 (0.56) | HSP90AA1KMT2AMEN1GPR52ALDH1A1 | |
| SCHEMBL9539946 | 0.79 | HSP90AA1 (0.54) | HSP90AA1KMT2AMEN1ALDH1A1HPGD | |
| SCHEMBL3694184 | 0.79 | HSP90AA1 (0.54) | HSP90AA1KMT2AMEN1GPR52ALDH1A1 | |
| SCHEMBL11397350 | 0.79 | HSP90AA1 (0.54) | HSP90AA1KMT2AMEN1GPR52ALDH1A1 | |
| SCHEMBL3923560 | 0.79 | HSP90AA1 (0.54) | HSP90AA1KMT2AMEN1ALDH1A1CYP1A2 | |
| SCHEMBL19243283 | 0.76 | SMN1; SMN2 (0.53) | HSP90AA1ALDH1A1HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | GB ACT, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | GB ACT, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | GB ACT, INC. (US) | 2018-07-03 | — | — | US | disclosed |
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2017-09-14 | — | — | US | disclosed |
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2017-09-14 | — | — | US | disclosed |
| US-9649305-B2 | PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649305-B2 | PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649305-B2 | PFKFB3 inhibitor and methods of use as an anti-cancer therapeutic | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2017-05-16 | — | — | US | disclosed |
| EP-2831047-B1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | ADVANCED CANCER THERAPEUTICS LLC (US) | 2017-05-03 | — | — | EP | disclosed |
| EP-2831047-B1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | ADVANCED CANCER THERAPEUTICS LLC (US) | 2017-05-03 | — | — | EP | disclosed |
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403769-B2 | Small molecule inhibitors of PFKFB3 and glycolytic flux and their methods of use as anti-cancer therapeutics | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2016-08-02 | — | — | US | disclosed |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2015-03-05 | — | — | US | disclosed |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | GB005, INC. | 2015-03-05 | — | — | US | disclosed |
| WO-2013148228-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2013-10-03 | — | — | WO | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011103557-A1 | SMALL MOLECULE INHIBITORS OF PFKFB3 AND GLYCOLYTIC FLUX AND THEIR METHODS OF USE AS ANTI-CANCER THERAPEUTICS | ADVANCED CANCER THERAPEUTICS, LLC (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170258783-A1 | PFKFB3 INHIBIT AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | PFKFB3, PFKFB1, PFKFB2 | HSP90AA1 3499/4885KMT2A 1403/4885MEN1 3601/4885 |
| US-10010542-B2 | PFKFB3 inhibit and methods of use as an anti-cancer therapeutic | PFKFB3, PFKFB1, PFKFB2 | HSP90AA1 3499/4885KMT2A 1403/4885MEN1 3601/4885 |
| US-20130059879-A1 | Small Molecule Inhibitors of PFKFB3 and Glycolytic Flux and Their Methods of Use as Anti-Cancer Therapeutics | PFKFB3, PFKFB1, PFKFB2 | HSP90AA1 3023/4885KMT2A 2275/4885MEN1 2284/4885 |
| US-20150064175-A1 | PFKFB3 INHIBITOR AND METHODS OF USE AS AN ANTI-CANCER THERAPEUTIC | PFKFB3, PFKFB1, PFKFB2 | HSP90AA1 3689/4885KMT2A 1320/4885MEN1 3445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.